Abbott director Starks buys shares in Form 4

Abbott Laboratories director Daniel J. Starks reported purchasing additional common shares of the company.

Rhea-AI Filing Summary

Abbott Laboratories director Daniel J. Starks reported purchasing additional common shares of the company. On February 4, 2026, he bought 4,967 common shares at a weighted average price of $109.1388 and 5,033 common shares at a weighted average price of $108.3328.

Following these transactions, Starks beneficially owns 6,738,817 Abbott common shares directly. He also reports 258 common shares held indirectly through the Alynne Starks 2012 Irrevocable Trust, for which he serves as sole trustee.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 3 txns

Insider STARKS DANIEL J

Role Director

Bought 10,000 shs ($1.09M)

Type	Security	Shares	Price	Value
Purchase	Common shares without par value	4,967	$109.1388	$542K
Purchase	Common shares without par value	5,033	$108.3328	$545K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 6,738,817 shares (Direct); Common shares without par value — 258 shares (Indirect, Alynne Starks 2012 Irrevocable Trust)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.8150 to $109.5204, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.7700 to $108.7150, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Daniel J. Starks report for Abbott Laboratories (ABT)?

Daniel J. Starks reported buying Abbott Laboratories common shares. On February 4, 2026, he purchased 4,967 shares at $109.1388 and 5,033 shares at $108.3328, according to the Form 4 insider trading report.

How many Abbott (ABT) shares does Daniel J. Starks own after this Form 4?

After the reported purchases, Daniel J. Starks beneficially owns 6,738,817 Abbott common shares directly. He also reports 258 additional shares held indirectly through the Alynne Starks 2012 Irrevocable Trust, where he serves as sole trustee.

What prices did Daniel J. Starks pay for his Abbott (ABT) share purchases?

Starks’ Abbott share purchases were reported at weighted average prices. He bought 4,967 shares at $109.1388 and 5,033 shares at $108.3328, with each figure reflecting multiple trades within a specified intraday price range.

What is the role of Daniel J. Starks at Abbott Laboratories (ABT)?

Daniel J. Starks is listed as a director of Abbott Laboratories. The Form 4 identifies his relationship to the issuer as a director, and the filing reports his direct and indirect beneficial ownership of Abbott common shares.

How are the 258 Abbott (ABT) shares in the Alynne Starks 2012 Irrevocable Trust reported?

The 258 Abbott common shares are reported as indirectly owned. They are held in the Alynne Starks 2012 Irrevocable Trust, and the filing notes that Daniel J. Starks is the sole trustee of this irrevocable trust.

Are the reported Abbott (ABT) transactions direct or indirect holdings for Daniel J. Starks?

The purchases of 4,967 and 5,033 Abbott common shares are reported as directly owned by Daniel J. Starks. Separately, 258 common shares are reported as indirectly owned through the Alynne Starks 2012 Irrevocable Trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/06/2026 - 08:04 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STARKS DANIEL J

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/04/2026		P		4,967	A	$109.1388(1)	6,733,784	D
Common shares without par value	02/04/2026		P		5,033	A	$108.3328(2)	6,738,817	D
Common shares without par value								258(3)	I	Alynne Starks 2012 Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.8150 to $109.5204, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.7700 to $108.7150, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.

	/s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.